These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31014551)

  • 21. [Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone].
    Gómez Valbuena I; Alonso Pérez L; Alioto D; Cañamares Orbis I; Ferrari Piquero JM
    Farm Hosp; 2014 Jul; 38(4):379-80. PubMed ID: 25137170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of SIADH due to pancreatic cancer was improved by tolvaptan].
    Matsuyama S; Ueo T; Ozawa T; Matsumoto A; Minami R; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(2):172-178. PubMed ID: 35153267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The syndrome of inappropriate antidiuresis (SIAD).
    Cuesta M; Thompson CJ
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):175-87. PubMed ID: 27156757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urea is successful in treating inappropriate antidiuretic hormone secretion in an infant.
    Dufek S; Booth C; Carroll A; Van't Hoff W; Kleta R; Bockenhauer D
    Acta Paediatr; 2017 Mar; 106(3):513-515. PubMed ID: 27935121
    [No Abstract]   [Full Text] [Related]  

  • 26. [SIADH and vaptans].
    Decaux G
    Ann Endocrinol (Paris); 2012 Apr; 73(2):130-4. PubMed ID: 22537510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma.
    Gürbüz F; Taştan M; Turan İ; Yüksel B
    J Clin Res Pediatr Endocrinol; 2019 May; 11(2):202-206. PubMed ID: 30257818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.
    Kai K; Tominaga N; Koitabashi K; Ichikawa D; Shibagaki Y
    CEN Case Rep; 2019 May; 8(2):112-118. PubMed ID: 30637666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R; Grossman AB; Kar P
    Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
    Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
    Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH).
    Kenz S; Haas CS; Werth SC; Bohnet S; Brabant G
    Ann Oncol; 2011 Dec; 22(12):2696. PubMed ID: 22021821
    [No Abstract]   [Full Text] [Related]  

  • 32. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability.
    Nakatani S; Ishimura E; Machiba Y; Nakatani A; Fujimoto K; Uedono H; Okute Y; Tsuda A; Mori K; Emoto M; Inaba M
    Nephrology (Carlton); 2018 Aug; 23(8):798-799. PubMed ID: 30920106
    [No Abstract]   [Full Text] [Related]  

  • 34. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?
    Sterns RH
    Am J Kidney Dis; 2018 Jun; 71(6):763-765. PubMed ID: 29801549
    [No Abstract]   [Full Text] [Related]  

  • 37. Tolvaptan: any evidence of efficacy in SIADH?
    Prescrire Int; 2010 Oct; 19(109):197-200. PubMed ID: 21180368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
    Trolle C; Rittig S; Frøkjær J; Jørgensen JO
    Ugeskr Laeger; 2012 Apr; 174(15):1019-22. PubMed ID: 22487409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SIADH with Severe Hyponatremia in an Elderly Man with Herpes Zoster Infection: A Causal or Casual Association?
    Foppiani L
    Intern Med; 2018 Dec; 57(23):3393-3398. PubMed ID: 29984775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD).
    Agraz-Pamplona I; Larrosa-Garcia M; Bury-Macias RP; Serón-Micas D; Montoro-Ronsano JB
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1473-1475. PubMed ID: 32514744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.